Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 10/03/2026 GMT			5-day change	1st Jan Change
246.95 ^DKK	-2.97%		+6.67%	-24.07%

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-10	European Stocks Surge in Tuesday Trading as Oil Concerns Ease Among Investors	MT

Health Care Down on Deal, Lawsuit Activity -- Health Care Roundup

Published on 02/09/2026 at 10:59 pm GMT

Dow Jones

NOVO NORDISK A/S

-2.97%

ELI LILLY AND COMPANY

-0.70%

Health-care companies fell as fears about health insurers offset deal and lawsuit activity.

Novo Nordisk rose after the Danish maker of obesity drugs Ozempic and Wegovy sued online pharmacy Hims & Hers in an attempt to block any further sales of copycat versions of its weight-loss medications.

Novo rival Eli Lilly rose after it struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash, whose experimental treatments would harness the body's own cells to fight disease.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

02-09-26 1759ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NOVO NORDISK A/S	246.95DKK	-2.97%	+6.67%	171B
	ELI LILLY AND COMPANY	1,001.35USD	-0.70%	-0.63%	895B

Latest news about Novo Nordisk A/S

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-10	European Stocks Surge in Tuesday Trading as Oil Concerns Ease Among Investors	MT
03-10	Norron Nordic Multi Strategy declined 0.32 percent in February - electrification and industrial stocks remain strong	FW
03-10	FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients	DJ
03-10	Norron Nordic Long/Short Equity increased 1.15 percent in February - portfolio tilted towards real assets, industrial companies and Nordic compounders	FW
03-10	Top Midday Stories: Amazon Kicks Off Large Cross-Atlantic Bond Sale; BioNTech Shares Fall on Co-Founders' Departure, Weak Earnings	MT
03-10	BofA Upgrades Hims & Hers Health to Neutral From Underperform as 'Worst Case De-Risked', Lifts Price Target to $23 From $12.50	MT
03-10	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
03-10	Novo Nordisk to 'Expeditiously, Holistically' Address US FDA Warning Letter Over New Jersey Facility	MT
03-10	Norron Sustainable Equity rose 3.36 percent in February - Vestum and Bravida top contributors	FW
03-10	Novo Nordisk Receives FDA Warning Letter Related to 2025 New Jersey Site Inspection	MT
03-10	Hims & Hers' Deal With Novo Nordisk Removes Litigation, Credit Risks, BofA Says	MT
03-10	Novo Nordisk Receives FDA Warning Letter Related to 2025 New Jersey Site Inspection	MT
03-10	Novo Nordisk Receives FDA Warning Letter Related to 2025 NJ Site Inspection	MT
03-10	Novo Nordisk says acknowledges receipt of warning letter, welcomes further dialogue with FDA	RE

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

03-27 - Ex-dividend date - 7.95 DKK

More about the company